Browse by Series:

Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More

Brielle Urciuoli
Published: Thursday, Apr 06, 2017



Brielle Urciuoli reports on full FDA approvals in breast cancer and non–small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.
Slider Left
Slider Right


Brielle Urciuoli reports on full FDA approvals in breast cancer and non–small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x